Differential profiling of breast cancer plasma proteome by isotope-coded affinity tagging method reveals biotinidase as a breast cancer biomarker

Un Beom Kang, Younghee Ahn, Jong W. Lee, Yong Hak Kim, Joon Kim, Myeong Hee Yu, Dong Young Noh, Cheolju Lee

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: Breast cancer is one of the leading causes of women's death worldwide. It is important to discover a reliable biomarker for the detection of breast cancer. Plasma is the most ideal source for cancer biomarker discovery since many cells cross-communicate through the secretion of soluble proteins into blood.Methods: Plasma proteomes obtained from 6 breast cancer patients and 6 normal healthy women were analyzed by using the isotope-coded affinity tag (ICAT) labeling approach and tandem mass spectrometry. All the plasma samples used were depleted of highly abundant 6 plasma proteins by immune-affinity column chromatography before ICAT labeling. Several proteins showing differential abundance level were selected based on literature searches and their specificity to the commercially available antibodies, and then verified by immunoblot assays.Results: A total of 155 proteins were identified and quantified by ICAT method. Among them, 33 proteins showed abundance changes by more than 1.5-fold between the plasmas of breast cancer patients and healthy women. We chose 5 proteins for the follow-up confirmation in the individual plasma samples using immunoblot assay. Four proteins, α1-acid glycoprotein 2, monocyte differentiation antigen CD14, biotinidase (BTD), and glutathione peroxidase 3, showed similar abundance ratio to ICAT result. Using a blind set of plasmas obtained from 21 breast cancer patients and 21 normal healthy controls, we confirmed that BTD was significantly down-regulated in breast cancer plasma (Wilcoxon rank-sum test, p = 0.002). BTD levels were lowered in all cancer grades (I-IV) except cancer grade zero. The area under the receiver operating characteristic curve of BTD was 0.78. Estrogen receptor status (p = 0.940) and progesterone receptor status (p = 0.440) were not associated with the plasma BTD levels.Conclusions: Our study suggests that BTD is a potential serological biomarker for the detection of breast cancer.

Original languageEnglish
Article number114
JournalBMC Cancer
Volume10
DOIs
Publication statusPublished - 2010 Mar 26

Fingerprint

Biotinidase
Isotope Labeling
Proteome
Tumor Biomarkers
Breast Neoplasms
Isotopes
Nonparametric Statistics
Proteins
Blood Proteins
Biomarkers
CD14 Antigens
Progesterone Receptors
Glutathione Peroxidase
Tandem Mass Spectrometry
Affinity Chromatography
ROC Curve
Estrogen Receptors
Cause of Death
Neoplasms
Glycoproteins

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Differential profiling of breast cancer plasma proteome by isotope-coded affinity tagging method reveals biotinidase as a breast cancer biomarker. / Kang, Un Beom; Ahn, Younghee; Lee, Jong W.; Kim, Yong Hak; Kim, Joon; Yu, Myeong Hee; Noh, Dong Young; Lee, Cheolju.

In: BMC Cancer, Vol. 10, 114, 26.03.2010.

Research output: Contribution to journalArticle

Kang, Un Beom ; Ahn, Younghee ; Lee, Jong W. ; Kim, Yong Hak ; Kim, Joon ; Yu, Myeong Hee ; Noh, Dong Young ; Lee, Cheolju. / Differential profiling of breast cancer plasma proteome by isotope-coded affinity tagging method reveals biotinidase as a breast cancer biomarker. In: BMC Cancer. 2010 ; Vol. 10.
@article{5f9d7113dff94f63bebd930e546f8808,
title = "Differential profiling of breast cancer plasma proteome by isotope-coded affinity tagging method reveals biotinidase as a breast cancer biomarker",
abstract = "Background: Breast cancer is one of the leading causes of women's death worldwide. It is important to discover a reliable biomarker for the detection of breast cancer. Plasma is the most ideal source for cancer biomarker discovery since many cells cross-communicate through the secretion of soluble proteins into blood.Methods: Plasma proteomes obtained from 6 breast cancer patients and 6 normal healthy women were analyzed by using the isotope-coded affinity tag (ICAT) labeling approach and tandem mass spectrometry. All the plasma samples used were depleted of highly abundant 6 plasma proteins by immune-affinity column chromatography before ICAT labeling. Several proteins showing differential abundance level were selected based on literature searches and their specificity to the commercially available antibodies, and then verified by immunoblot assays.Results: A total of 155 proteins were identified and quantified by ICAT method. Among them, 33 proteins showed abundance changes by more than 1.5-fold between the plasmas of breast cancer patients and healthy women. We chose 5 proteins for the follow-up confirmation in the individual plasma samples using immunoblot assay. Four proteins, α1-acid glycoprotein 2, monocyte differentiation antigen CD14, biotinidase (BTD), and glutathione peroxidase 3, showed similar abundance ratio to ICAT result. Using a blind set of plasmas obtained from 21 breast cancer patients and 21 normal healthy controls, we confirmed that BTD was significantly down-regulated in breast cancer plasma (Wilcoxon rank-sum test, p = 0.002). BTD levels were lowered in all cancer grades (I-IV) except cancer grade zero. The area under the receiver operating characteristic curve of BTD was 0.78. Estrogen receptor status (p = 0.940) and progesterone receptor status (p = 0.440) were not associated with the plasma BTD levels.Conclusions: Our study suggests that BTD is a potential serological biomarker for the detection of breast cancer.",
author = "Kang, {Un Beom} and Younghee Ahn and Lee, {Jong W.} and Kim, {Yong Hak} and Joon Kim and Yu, {Myeong Hee} and Noh, {Dong Young} and Cheolju Lee",
year = "2010",
month = "3",
day = "26",
doi = "10.1186/1471-2407-10-114",
language = "English",
volume = "10",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Differential profiling of breast cancer plasma proteome by isotope-coded affinity tagging method reveals biotinidase as a breast cancer biomarker

AU - Kang, Un Beom

AU - Ahn, Younghee

AU - Lee, Jong W.

AU - Kim, Yong Hak

AU - Kim, Joon

AU - Yu, Myeong Hee

AU - Noh, Dong Young

AU - Lee, Cheolju

PY - 2010/3/26

Y1 - 2010/3/26

N2 - Background: Breast cancer is one of the leading causes of women's death worldwide. It is important to discover a reliable biomarker for the detection of breast cancer. Plasma is the most ideal source for cancer biomarker discovery since many cells cross-communicate through the secretion of soluble proteins into blood.Methods: Plasma proteomes obtained from 6 breast cancer patients and 6 normal healthy women were analyzed by using the isotope-coded affinity tag (ICAT) labeling approach and tandem mass spectrometry. All the plasma samples used were depleted of highly abundant 6 plasma proteins by immune-affinity column chromatography before ICAT labeling. Several proteins showing differential abundance level were selected based on literature searches and their specificity to the commercially available antibodies, and then verified by immunoblot assays.Results: A total of 155 proteins were identified and quantified by ICAT method. Among them, 33 proteins showed abundance changes by more than 1.5-fold between the plasmas of breast cancer patients and healthy women. We chose 5 proteins for the follow-up confirmation in the individual plasma samples using immunoblot assay. Four proteins, α1-acid glycoprotein 2, monocyte differentiation antigen CD14, biotinidase (BTD), and glutathione peroxidase 3, showed similar abundance ratio to ICAT result. Using a blind set of plasmas obtained from 21 breast cancer patients and 21 normal healthy controls, we confirmed that BTD was significantly down-regulated in breast cancer plasma (Wilcoxon rank-sum test, p = 0.002). BTD levels were lowered in all cancer grades (I-IV) except cancer grade zero. The area under the receiver operating characteristic curve of BTD was 0.78. Estrogen receptor status (p = 0.940) and progesterone receptor status (p = 0.440) were not associated with the plasma BTD levels.Conclusions: Our study suggests that BTD is a potential serological biomarker for the detection of breast cancer.

AB - Background: Breast cancer is one of the leading causes of women's death worldwide. It is important to discover a reliable biomarker for the detection of breast cancer. Plasma is the most ideal source for cancer biomarker discovery since many cells cross-communicate through the secretion of soluble proteins into blood.Methods: Plasma proteomes obtained from 6 breast cancer patients and 6 normal healthy women were analyzed by using the isotope-coded affinity tag (ICAT) labeling approach and tandem mass spectrometry. All the plasma samples used were depleted of highly abundant 6 plasma proteins by immune-affinity column chromatography before ICAT labeling. Several proteins showing differential abundance level were selected based on literature searches and their specificity to the commercially available antibodies, and then verified by immunoblot assays.Results: A total of 155 proteins were identified and quantified by ICAT method. Among them, 33 proteins showed abundance changes by more than 1.5-fold between the plasmas of breast cancer patients and healthy women. We chose 5 proteins for the follow-up confirmation in the individual plasma samples using immunoblot assay. Four proteins, α1-acid glycoprotein 2, monocyte differentiation antigen CD14, biotinidase (BTD), and glutathione peroxidase 3, showed similar abundance ratio to ICAT result. Using a blind set of plasmas obtained from 21 breast cancer patients and 21 normal healthy controls, we confirmed that BTD was significantly down-regulated in breast cancer plasma (Wilcoxon rank-sum test, p = 0.002). BTD levels were lowered in all cancer grades (I-IV) except cancer grade zero. The area under the receiver operating characteristic curve of BTD was 0.78. Estrogen receptor status (p = 0.940) and progesterone receptor status (p = 0.440) were not associated with the plasma BTD levels.Conclusions: Our study suggests that BTD is a potential serological biomarker for the detection of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=77953475291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953475291&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-10-114

DO - 10.1186/1471-2407-10-114

M3 - Article

C2 - 20346108

AN - SCOPUS:77953475291

VL - 10

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 114

ER -